金斯瑞生物科技：降目标价至16.5港元，维持“增持”评级-20260312

Investment Rating - The report maintains an "Overweight" rating for Kingsoft Biotech (01548) despite a downward revision of earnings estimates [1] Core Insights - Morgan Stanley has adjusted its earnings forecast for Kingsoft Biotech for the years 2026 to 2030 down by 1% to 13% following the company's profit warning [1] - The target price for Kingsoft Biotech has been reduced from HKD 18.3 to HKD 16.5 [1]